Osimertinib

Introduction The treatment of EGFR-mutated non-small cell lung cancer (NSCLC) has evolved significantly over the past two decades. Targeted therapies known as EGFR inhibitors have transformed patient outcomes by specifically blocking cancer cells with EGFR mutations while minimizing damage to healthy cells. Among the most commonly used EGFR inhibitors are Erlotinib, Gefitinib, and Osimertinib. While

Introduction The treatment landscape for non-small cell lung cancer (NSCLC) has changed dramatically over the past decade. For patients whose tumors carry specific EGFR (Epidermal Growth Factor Receptor) mutations, targeted therapies have significantly improved survival and quality of life compared with traditional chemotherapy. Among these targeted treatments, Osimertinib has become the preferred first-line treatment for

Introduction For many patients with EGFR-mutated non-small cell lung cancer (NSCLC), targeted therapy has transformed treatment outcomes. Earlier EGFR inhibitors helped many patients control their cancer for months or even years. However, over time, some cancers develop resistance, making these medicines less effective. One of the most common resistance mechanisms is the EGFR T790M mutation.